company background image
1530

3SBio SEHK:1530 Stock Report

Last Price

HK$8.08

Market Cap

HK$19.7b

7D

17.4%

1Y

21.7%

Updated

27 Nov, 2022

Data

Company Financials +
1530 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends2/6

1530 Stock Overview

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People’s Republic of China.

3SBio Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for 3SBio
Historical stock prices
Current Share PriceHK$8.08
52 Week HighHK$8.09
52 Week LowHK$4.72
Beta0.61
1 Month Change42.50%
3 Month Change57.50%
1 Year Change21.69%
3 Year Change-28.50%
5 Year Change-45.77%
Change since IPO-13.58%

Recent News & Updates

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Nov 24
Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Oct 21
We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Recent updates

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Nov 24
Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Oct 21
We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

Oct 04
3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

Apr 21
Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Mar 31
We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Dec 09
We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Nov 21
An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 10
We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Aug 22
3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

May 21
3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16
Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?

Mar 11
What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?

Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 18
Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued

Jan 31
An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued

A Look At 3SBio's (HKG:1530) Share Price Returns

Jan 03
A Look At 3SBio's (HKG:1530) Share Price Returns

Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?

Dec 16
Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?

What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?

Dec 01
What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?

Shareholder Returns

1530HK BiotechsHK Market
7D17.4%-9.4%-0.2%
1Y21.7%-52.0%-24.6%

Return vs Industry: 1530 exceeded the Hong Kong Biotechs industry which returned -52% over the past year.

Return vs Market: 1530 exceeded the Hong Kong Market which returned -24.6% over the past year.

Price Volatility

Is 1530's price volatile compared to industry and market?
1530 volatility
1530 Average Weekly Movement7.3%
Biotechs Industry Average Movement11.3%
Market Average Movement8.0%
10% most volatile stocks in HK Market15.0%
10% least volatile stocks in HK Market3.9%

Stable Share Price: 1530 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 1530's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19935,160Jing Louhttps://www.3sbio.com

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People’s Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis.

3SBio Inc. Fundamentals Summary

How do 3SBio's earnings and revenue compare to its market cap?
1530 fundamental statistics
Market CapHK$19.71b
Earnings (TTM)HK$1.86b
Revenue (TTM)HK$6.94b

10.6x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1530 income statement (TTM)
RevenueCN¥6.37b
Cost of RevenueCN¥1.11b
Gross ProfitCN¥5.25b
Other ExpensesCN¥3.55b
EarningsCN¥1.71b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.70
Gross Margin82.52%
Net Profit Margin26.81%
Debt/Equity Ratio26.4%

How did 1530 perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

24%

Payout Ratio